Key Insights
The global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market is experiencing robust growth, projected to reach \$243.29 million in 2025 and maintain a Compound Annual Growth Rate (CAGR) of 6.41% from 2025 to 2033. This expansion is driven by several key factors. Firstly, the increasing complexity of drug development, coupled with rising R&D costs, is compelling pharmaceutical companies to outsource specific stages of the drug lifecycle to specialized CDMOs. This allows pharmaceutical companies to focus on core competencies while leveraging the expertise and economies of scale offered by CDMOs. Secondly, the surge in demand for biologics and advanced therapies, such as cell and gene therapies, is fueling significant growth within the CDMO sector. These therapies require specialized manufacturing capabilities and expertise that many pharmaceutical companies lack in-house. Finally, the regulatory landscape is also playing a role, with increasing scrutiny and demand for stringent quality control and compliance, necessitating partnerships with CDMOs possessing robust quality systems. The market segmentation reveals a significant demand across all research phases (pre-clinical to Phase IV), with a strong emphasis on services like Active Pharmaceutical Ingredient (API) manufacturing and finished dosage formulation development. The geographical distribution is expected to be skewed towards North America and Europe initially, but regions such as Asia are expected to witness rapid growth due to increasing investments in pharmaceutical infrastructure and manufacturing capabilities.
The competitive landscape is highly fragmented, with a large number of CDMOs catering to diverse needs and therapeutic areas. Key players such as Lonza Group, Catalent Inc., and Thermo Fisher Scientific (through its PPD and Patheon acquisitions) are consolidating their market share through acquisitions and strategic partnerships. However, smaller, specialized CDMOs continue to thrive by focusing on niche areas like high-potency APIs or specific therapeutic areas. The future trajectory of the CDMO market will likely involve further consolidation, technological advancements in manufacturing processes (like continuous manufacturing), and an increased focus on digitalization and data analytics to optimize efficiency and accelerate drug development timelines. The market will also see increased focus on sustainability and environmentally friendly manufacturing practices. This will be influenced by increasing global regulations in this area.
This comprehensive report provides an in-depth analysis of the Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market, offering valuable insights for stakeholders from 2019-2033. The study period covers historical data (2019-2024), with 2025 as the base and estimated year, and a forecast extending to 2033. The market is segmented by Research Phase (CRO: Pre-clinical, Phase I, Phase II, Phase III, Phase IV) and Service Type (CMO: API Manufacturing, High Potency API (HPAPI), Finished Dosage Formulation (FDF) Development & Manufacturing, Solid Dose Formulation, Injectable Dose Formulation, Secondary Packaging). Key players analyzed include LSK Global Pharma Service Co Ltd, Thermo Fisher Scientific (including PPD and Patheon), Hangzhou Tigermed Consulting Co Ltd, Famar SA, PAREXEL International Corporation, CMIC Holdings Co Ltd, PRA Health Sciences Inc (Icon PLC), Lonza Group, Pfizer CentreSource, SGS Life Science Services SA, Samsung Bioepis Co Ltd, Jubilant Pharmova Ltd, WuXi AppTec Inc, Tesa Labtec GmbH (TESA SE), Syneos Health Inc, IQVIA Holdings Inc, ARX LLC, Tapemark, Catalent Inc, Boehringer Ingelheim Group, Novotech Pty Ltd, LabCorp Drug Development, Aenova Holding GmbH, Recipharm AB, Sagimet Biosciences (3V Biosciences Inc), Baxter Biopharma Solutions (Baxter International Inc), and Quanticate Ltd. The report projects a market value reaching xx Million by 2033.
-Market.png)
Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Market Composition & Trends
The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market exhibits a moderately concentrated landscape, with a few large players holding significant market share, while numerous smaller companies cater to niche needs. Market share distribution is influenced by factors such as technological capabilities, geographic reach, and regulatory compliance. Innovation is driven by advancements in drug delivery systems, process optimization, and analytical technologies. The regulatory landscape, characterized by stringent GMP guidelines and evolving regulatory approvals, impacts market dynamics. Substitute products, such as in-house manufacturing by larger pharmaceutical companies, pose a competitive threat. End-users primarily include pharmaceutical and biotechnology companies seeking cost-effective and efficient drug development and manufacturing solutions. Mergers and acquisitions (M&A) are prevalent, with deal values averaging xx Million in recent years, driven by the desire for expansion, technological capabilities, and diversification.
- Market Concentration: Moderately concentrated, with top 5 players holding approximately xx% market share.
- Innovation Catalysts: Advancements in drug delivery, process optimization, and analytical technologies.
- Regulatory Landscape: Stringent GMP guidelines and evolving approval processes.
- Substitute Products: In-house manufacturing by large pharmaceutical companies.
- End-User Profile: Pharmaceutical and biotechnology companies.
- M&A Activity: Frequent M&A deals with average values of xx Million.
-Market.png)
Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Industry Evolution
The CDMO market has experienced substantial growth, driven by factors such as the increasing outsourcing of drug development and manufacturing by pharmaceutical companies, a rising demand for biologics and specialized therapies, and the accelerated adoption of innovative technologies. Technological advancements such as automation, continuous manufacturing, and AI-powered process optimization have significantly improved efficiency and reduced costs. Shifting consumer demands, with an increasing focus on personalized medicine and advanced therapies, necessitate the development of specialized CDMO services. From 2019 to 2024, the market witnessed a Compound Annual Growth Rate (CAGR) of xx%, and this trajectory is projected to continue, with a forecast CAGR of xx% from 2025 to 2033. Adoption of advanced technologies like continuous manufacturing is expected to reach xx% by 2033. The market is also witnessing a rise in demand for cell and gene therapy manufacturing services.
Leading Regions, Countries, or Segments in Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market
North America holds a dominant position in the CDMO market, driven by strong R&D investments, a large pool of skilled professionals, and advanced manufacturing capabilities. Within this region, the United States accounts for a significant portion of the market share. Europe also holds a substantial market share, attributed to its well-established pharmaceutical industry and a favorable regulatory environment. Asia-Pacific is an emerging region with significant growth potential, fueled by increasing healthcare spending and a burgeoning pharmaceutical industry.
- Key Drivers (North America):
- High R&D investment.
- Skilled workforce.
- Advanced manufacturing infrastructure.
- Strong regulatory support.
- Key Drivers (Europe):
- Established pharmaceutical industry.
- Favorable regulatory environment.
- Access to skilled talent.
- Key Drivers (Asia-Pacific):
- Increasing healthcare spending.
- Growing pharmaceutical industry.
- Cost-effective manufacturing capabilities.
By Research Phase, Phase III clinical trials represent a significant segment within the CRO market, due to the higher investment associated with large-scale clinical trials, leading to increased demand for CDMO services. In the CMO segment, API manufacturing is the largest portion of the market due to its importance in the early stage of drug development. High-Potency API (HPAPI) manufacturing is also a rapidly growing segment due to the increasing prevalence of potent drugs in the pharmaceutical pipeline.
Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Product Innovations
Recent innovations include the development of advanced drug delivery systems such as liposomes and nanoparticles, enabling targeted drug delivery and improved efficacy. Continuous manufacturing processes offer enhanced productivity and reduced manufacturing costs, while the integration of AI and machine learning in process optimization significantly enhances efficiency and quality control. These innovations increase product quality and reduce production times.
Propelling Factors for Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Growth
Technological advancements in drug delivery systems and manufacturing processes are key drivers. The increasing outsourcing of drug development and manufacturing by pharmaceutical companies reduces internal operational costs and enables companies to focus on research and development activities. Favorable regulatory policies and government initiatives promoting the pharmaceutical industry encourage growth.
Obstacles in the Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Market
Stringent regulatory requirements and approvals can create delays and increase compliance costs. Supply chain disruptions, such as raw material shortages or geopolitical instability, can impact manufacturing and timelines. Intense competition among existing and new entrants, with companies constantly vying for market share, creates challenges. The overall impact of these obstacles reduces profitability.
Future Opportunities in Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market
Emerging markets in developing countries present significant expansion opportunities. The development of personalized medicine and advanced therapies like cell and gene therapies creates new service demands. The integration of advanced technologies like AI and automation further creates new opportunities for market expansion and enhancement of services.
Major Players in the Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Ecosystem
- LSK Global Pharma Service Co Ltd
- Pharmaceutical Product Development LLC (Thermo Fisher Scientific Inc)
- Hangzhou Tigermed Consulting Co Ltd
- Famar SA
- PAREXEL International Corporation
- CMIC Holdings Co Ltd
- PRA Health Sciences Inc (Icon PLC)
- Lonza Group
- Pfizer CentreSource
- SGS Life Science Services SA
- Samsung Bioepis Co Ltd
- Jubilant Pharmova Ltd
- WuXi AppTec Inc
- Tesa Labtec GmbH (TESA SE)
- Syneos Health Inc
- IQVIA Holdings Inc
- ARX LLC
- Tapemark
- Catalent Inc
- Boehringer Ingelheim Group
- Novotech Pty Ltd
- LabCorp Drug Development
- Aenova Holding GmbH
- Recipharm AB
- Sagimet Biosciences (3V Biosciences Inc)
- Baxter Biopharma Solutions (Baxter International Inc)
- Quanticate Ltd
Key Developments in Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Industry
- January 2024: FAMAR and Lavipharm announce a new collaboration, expanding FAMAR's European CDMO presence.
- January 2024: Pluri launches "pluriCDMO," a new cell therapy manufacturing division with a 47,000-ft2 GMP facility.
- October 2023: IQVIA and Argenx collaborate on innovative pharmacovigilance services for rare autoimmune diseases.
Strategic Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Market Forecast
The CDMO market is poised for continued robust growth, driven by technological advancements, increased outsourcing by pharmaceutical companies, and the expanding need for specialized manufacturing capabilities. The market's potential is vast, particularly in emerging markets and advanced therapeutic areas, promising significant opportunities for industry players who can adapt to evolving trends and technological innovations. The projected market size reflects this sustained growth and expansion.
Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Segmentation
-
1. Service Type CMO Segment
-
1.1. Active P
- 1.1.1. Small Molecule
- 1.1.2. Large Molecule
- 1.1.3. High Potency (HPAPI)
-
1.2. Finished
-
1.2.1. Solid Dose Formulation
- 1.2.1.1. Tablets
- 1.2.1.2. Others (Capsules, Powders, etc.)
- 1.2.2. Liquid Dose Formulation
- 1.2.3. Injectable Dose Formulation
-
1.2.1. Solid Dose Formulation
- 1.3. Secondary Packaging
-
1.1. Active P
-
2. Research Phase CRO Segment
- 2.1. Pre-clinical
- 2.2. Phase I
- 2.3. Phase II
- 2.4. Phase III
- 2.5. Phase IV
Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Segmentation By Geography
-
1. North America
- 1.1. United States
- 1.2. Canada
-
2. Europe
- 2.1. United Kingdom
- 2.2. Germany
- 2.3. France
- 2.4. Italy
-
3. Asia
- 3.1. China
- 3.2. India
- 3.3. Japan
- 3.4. Australia and New Zealand
-
4. Latin America
- 4.1. Brazil
- 4.2. Mexico
- 4.3. Argentina
-
5. Middle East and Africa
- 5.1. United Arab Emirates
- 5.2. Saudi Arabia
- 5.3. South Africa
- 6. North America
- 7. Europe
- 8. Asia
- 9. Australia and New Zealand
- 10. Latin America
- 11. Middle East and Africa
-Market.png)
Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2019-2033 |
| Base Year | 2024 |
| Estimated Year | 2025 |
| Forecast Period | 2025-2033 |
| Historical Period | 2019-2024 |
| Growth Rate | CAGR of 6.41% from 2019-2033 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Increasing Outsourcing Volume by Big Pharmaceutical Companies; Advent of CDMO Model into the Market; Increasing Investment in R&D
- 3.3. Market Restrains
- 3.3.1. Increasing Lead Time and Logistics Costs; Stringent Regulatory Requirements; Capacity Utilization Issues Affecting the Profitability of CMOs
- 3.4. Market Trends
- 3.4.1. Increasing Investment in R&D Drives the Market
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 5.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 5.1.1. Active P
- 5.1.1.1. Small Molecule
- 5.1.1.2. Large Molecule
- 5.1.1.3. High Potency (HPAPI)
- 5.1.2. Finished
- 5.1.2.1. Solid Dose Formulation
- 5.1.2.1.1. Tablets
- 5.1.2.1.2. Others (Capsules, Powders, etc.)
- 5.1.2.2. Liquid Dose Formulation
- 5.1.2.3. Injectable Dose Formulation
- 5.1.2.1. Solid Dose Formulation
- 5.1.3. Secondary Packaging
- 5.1.1. Active P
- 5.2. Market Analysis, Insights and Forecast - by Research Phase CRO Segment
- 5.2.1. Pre-clinical
- 5.2.2. Phase I
- 5.2.3. Phase II
- 5.2.4. Phase III
- 5.2.5. Phase IV
- 5.3. Market Analysis, Insights and Forecast - by Region
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. Asia
- 5.3.4. Latin America
- 5.3.5. Middle East and Africa
- 5.3.6. North America
- 5.3.7. Europe
- 5.3.8. Asia
- 5.3.9. Australia and New Zealand
- 5.3.10. Latin America
- 5.3.11. Middle East and Africa
- 5.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 6. North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 6.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 6.1.1. Active P
- 6.1.1.1. Small Molecule
- 6.1.1.2. Large Molecule
- 6.1.1.3. High Potency (HPAPI)
- 6.1.2. Finished
- 6.1.2.1. Solid Dose Formulation
- 6.1.2.1.1. Tablets
- 6.1.2.1.2. Others (Capsules, Powders, etc.)
- 6.1.2.2. Liquid Dose Formulation
- 6.1.2.3. Injectable Dose Formulation
- 6.1.2.1. Solid Dose Formulation
- 6.1.3. Secondary Packaging
- 6.1.1. Active P
- 6.2. Market Analysis, Insights and Forecast - by Research Phase CRO Segment
- 6.2.1. Pre-clinical
- 6.2.2. Phase I
- 6.2.3. Phase II
- 6.2.4. Phase III
- 6.2.5. Phase IV
- 6.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 7. Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 7.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 7.1.1. Active P
- 7.1.1.1. Small Molecule
- 7.1.1.2. Large Molecule
- 7.1.1.3. High Potency (HPAPI)
- 7.1.2. Finished
- 7.1.2.1. Solid Dose Formulation
- 7.1.2.1.1. Tablets
- 7.1.2.1.2. Others (Capsules, Powders, etc.)
- 7.1.2.2. Liquid Dose Formulation
- 7.1.2.3. Injectable Dose Formulation
- 7.1.2.1. Solid Dose Formulation
- 7.1.3. Secondary Packaging
- 7.1.1. Active P
- 7.2. Market Analysis, Insights and Forecast - by Research Phase CRO Segment
- 7.2.1. Pre-clinical
- 7.2.2. Phase I
- 7.2.3. Phase II
- 7.2.4. Phase III
- 7.2.5. Phase IV
- 7.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 8. Asia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 8.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 8.1.1. Active P
- 8.1.1.1. Small Molecule
- 8.1.1.2. Large Molecule
- 8.1.1.3. High Potency (HPAPI)
- 8.1.2. Finished
- 8.1.2.1. Solid Dose Formulation
- 8.1.2.1.1. Tablets
- 8.1.2.1.2. Others (Capsules, Powders, etc.)
- 8.1.2.2. Liquid Dose Formulation
- 8.1.2.3. Injectable Dose Formulation
- 8.1.2.1. Solid Dose Formulation
- 8.1.3. Secondary Packaging
- 8.1.1. Active P
- 8.2. Market Analysis, Insights and Forecast - by Research Phase CRO Segment
- 8.2.1. Pre-clinical
- 8.2.2. Phase I
- 8.2.3. Phase II
- 8.2.4. Phase III
- 8.2.5. Phase IV
- 8.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 9. Latin America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 9.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 9.1.1. Active P
- 9.1.1.1. Small Molecule
- 9.1.1.2. Large Molecule
- 9.1.1.3. High Potency (HPAPI)
- 9.1.2. Finished
- 9.1.2.1. Solid Dose Formulation
- 9.1.2.1.1. Tablets
- 9.1.2.1.2. Others (Capsules, Powders, etc.)
- 9.1.2.2. Liquid Dose Formulation
- 9.1.2.3. Injectable Dose Formulation
- 9.1.2.1. Solid Dose Formulation
- 9.1.3. Secondary Packaging
- 9.1.1. Active P
- 9.2. Market Analysis, Insights and Forecast - by Research Phase CRO Segment
- 9.2.1. Pre-clinical
- 9.2.2. Phase I
- 9.2.3. Phase II
- 9.2.4. Phase III
- 9.2.5. Phase IV
- 9.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 10. Middle East and Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 10.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 10.1.1. Active P
- 10.1.1.1. Small Molecule
- 10.1.1.2. Large Molecule
- 10.1.1.3. High Potency (HPAPI)
- 10.1.2. Finished
- 10.1.2.1. Solid Dose Formulation
- 10.1.2.1.1. Tablets
- 10.1.2.1.2. Others (Capsules, Powders, etc.)
- 10.1.2.2. Liquid Dose Formulation
- 10.1.2.3. Injectable Dose Formulation
- 10.1.2.1. Solid Dose Formulation
- 10.1.3. Secondary Packaging
- 10.1.1. Active P
- 10.2. Market Analysis, Insights and Forecast - by Research Phase CRO Segment
- 10.2.1. Pre-clinical
- 10.2.2. Phase I
- 10.2.3. Phase II
- 10.2.4. Phase III
- 10.2.5. Phase IV
- 10.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 11. North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 11.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 11.1.1. Active P
- 11.1.1.1. Small Molecule
- 11.1.1.2. Large Molecule
- 11.1.1.3. High Potency (HPAPI)
- 11.1.2. Finished
- 11.1.2.1. Solid Dose Formulation
- 11.1.2.1.1. Tablets
- 11.1.2.1.2. Others (Capsules, Powders, etc.)
- 11.1.2.2. Liquid Dose Formulation
- 11.1.2.3. Injectable Dose Formulation
- 11.1.2.1. Solid Dose Formulation
- 11.1.3. Secondary Packaging
- 11.1.1. Active P
- 11.2. Market Analysis, Insights and Forecast - by Research Phase CRO Segment
- 11.2.1. Pre-clinical
- 11.2.2. Phase I
- 11.2.3. Phase II
- 11.2.4. Phase III
- 11.2.5. Phase IV
- 11.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 12. Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 12.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 12.1.1. Active P
- 12.1.1.1. Small Molecule
- 12.1.1.2. Large Molecule
- 12.1.1.3. High Potency (HPAPI)
- 12.1.2. Finished
- 12.1.2.1. Solid Dose Formulation
- 12.1.2.1.1. Tablets
- 12.1.2.1.2. Others (Capsules, Powders, etc.)
- 12.1.2.2. Liquid Dose Formulation
- 12.1.2.3. Injectable Dose Formulation
- 12.1.2.1. Solid Dose Formulation
- 12.1.3. Secondary Packaging
- 12.1.1. Active P
- 12.2. Market Analysis, Insights and Forecast - by Research Phase CRO Segment
- 12.2.1. Pre-clinical
- 12.2.2. Phase I
- 12.2.3. Phase II
- 12.2.4. Phase III
- 12.2.5. Phase IV
- 12.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 13. Asia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 13.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 13.1.1. Active P
- 13.1.1.1. Small Molecule
- 13.1.1.2. Large Molecule
- 13.1.1.3. High Potency (HPAPI)
- 13.1.2. Finished
- 13.1.2.1. Solid Dose Formulation
- 13.1.2.1.1. Tablets
- 13.1.2.1.2. Others (Capsules, Powders, etc.)
- 13.1.2.2. Liquid Dose Formulation
- 13.1.2.3. Injectable Dose Formulation
- 13.1.2.1. Solid Dose Formulation
- 13.1.3. Secondary Packaging
- 13.1.1. Active P
- 13.2. Market Analysis, Insights and Forecast - by Research Phase CRO Segment
- 13.2.1. Pre-clinical
- 13.2.2. Phase I
- 13.2.3. Phase II
- 13.2.4. Phase III
- 13.2.5. Phase IV
- 13.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 14. Australia and New Zealand Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 14.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 14.1.1. Active P
- 14.1.1.1. Small Molecule
- 14.1.1.2. Large Molecule
- 14.1.1.3. High Potency (HPAPI)
- 14.1.2. Finished
- 14.1.2.1. Solid Dose Formulation
- 14.1.2.1.1. Tablets
- 14.1.2.1.2. Others (Capsules, Powders, etc.)
- 14.1.2.2. Liquid Dose Formulation
- 14.1.2.3. Injectable Dose Formulation
- 14.1.2.1. Solid Dose Formulation
- 14.1.3. Secondary Packaging
- 14.1.1. Active P
- 14.2. Market Analysis, Insights and Forecast - by Research Phase CRO Segment
- 14.2.1. Pre-clinical
- 14.2.2. Phase I
- 14.2.3. Phase II
- 14.2.4. Phase III
- 14.2.5. Phase IV
- 14.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 15. Latin America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 15.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 15.1.1. Active P
- 15.1.1.1. Small Molecule
- 15.1.1.2. Large Molecule
- 15.1.1.3. High Potency (HPAPI)
- 15.1.2. Finished
- 15.1.2.1. Solid Dose Formulation
- 15.1.2.1.1. Tablets
- 15.1.2.1.2. Others (Capsules, Powders, etc.)
- 15.1.2.2. Liquid Dose Formulation
- 15.1.2.3. Injectable Dose Formulation
- 15.1.2.1. Solid Dose Formulation
- 15.1.3. Secondary Packaging
- 15.1.1. Active P
- 15.2. Market Analysis, Insights and Forecast - by Research Phase CRO Segment
- 15.2.1. Pre-clinical
- 15.2.2. Phase I
- 15.2.3. Phase II
- 15.2.4. Phase III
- 15.2.5. Phase IV
- 15.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 16. Middle East and Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 16.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 16.1.1. Active P
- 16.1.1.1. Small Molecule
- 16.1.1.2. Large Molecule
- 16.1.1.3. High Potency (HPAPI)
- 16.1.2. Finished
- 16.1.2.1. Solid Dose Formulation
- 16.1.2.1.1. Tablets
- 16.1.2.1.2. Others (Capsules, Powders, etc.)
- 16.1.2.2. Liquid Dose Formulation
- 16.1.2.3. Injectable Dose Formulation
- 16.1.2.1. Solid Dose Formulation
- 16.1.3. Secondary Packaging
- 16.1.1. Active P
- 16.2. Market Analysis, Insights and Forecast - by Research Phase CRO Segment
- 16.2.1. Pre-clinical
- 16.2.2. Phase I
- 16.2.3. Phase II
- 16.2.4. Phase III
- 16.2.5. Phase IV
- 16.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 17. North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 17.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 17.1.1.
- 18. Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 18.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 18.1.1.
- 19. Asia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 19.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 19.1.1.
- 20. Australia and New Zealand Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 20.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 20.1.1.
- 21. Latin America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 21.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 21.1.1.
- 22. Middle East and Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 22.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 22.1.1.
- 23. Competitive Analysis
- 23.1. Global Market Share Analysis 2024
- 23.2. Company Profiles
- 23.2.1 LSK Global Pharma Service Co Ltd
- 23.2.1.1. Overview
- 23.2.1.2. Products
- 23.2.1.3. SWOT Analysis
- 23.2.1.4. Recent Developments
- 23.2.1.5. Financials (Based on Availability)
- 23.2.2 Pharmaceutical Product Development LLC (Thermo Fisher Scientific Inc )
- 23.2.2.1. Overview
- 23.2.2.2. Products
- 23.2.2.3. SWOT Analysis
- 23.2.2.4. Recent Developments
- 23.2.2.5. Financials (Based on Availability)
- 23.2.3 Hangzhou Tigermed Consulting Co Ltd
- 23.2.3.1. Overview
- 23.2.3.2. Products
- 23.2.3.3. SWOT Analysis
- 23.2.3.4. Recent Developments
- 23.2.3.5. Financials (Based on Availability)
- 23.2.4 Famar SA
- 23.2.4.1. Overview
- 23.2.4.2. Products
- 23.2.4.3. SWOT Analysis
- 23.2.4.4. Recent Developments
- 23.2.4.5. Financials (Based on Availability)
- 23.2.5 PAREXEL International Corporation
- 23.2.5.1. Overview
- 23.2.5.2. Products
- 23.2.5.3. SWOT Analysis
- 23.2.5.4. Recent Developments
- 23.2.5.5. Financials (Based on Availability)
- 23.2.6 CMIC Holdings Co Ltd
- 23.2.6.1. Overview
- 23.2.6.2. Products
- 23.2.6.3. SWOT Analysis
- 23.2.6.4. Recent Developments
- 23.2.6.5. Financials (Based on Availability)
- 23.2.7 PRA Health Sciences Inc (Icon PLC)
- 23.2.7.1. Overview
- 23.2.7.2. Products
- 23.2.7.3. SWOT Analysis
- 23.2.7.4. Recent Developments
- 23.2.7.5. Financials (Based on Availability)
- 23.2.8 Lonza Group
- 23.2.8.1. Overview
- 23.2.8.2. Products
- 23.2.8.3. SWOT Analysis
- 23.2.8.4. Recent Developments
- 23.2.8.5. Financials (Based on Availability)
- 23.2.9 Pfizer CentreSource
- 23.2.9.1. Overview
- 23.2.9.2. Products
- 23.2.9.3. SWOT Analysis
- 23.2.9.4. Recent Developments
- 23.2.9.5. Financials (Based on Availability)
- 23.2.10 SGS Life Science Services SA
- 23.2.10.1. Overview
- 23.2.10.2. Products
- 23.2.10.3. SWOT Analysis
- 23.2.10.4. Recent Developments
- 23.2.10.5. Financials (Based on Availability)
- 23.2.11 Samsung Bioepis Co Ltd
- 23.2.11.1. Overview
- 23.2.11.2. Products
- 23.2.11.3. SWOT Analysis
- 23.2.11.4. Recent Developments
- 23.2.11.5. Financials (Based on Availability)
- 23.2.12 Jubilant Pharmova Ltd
- 23.2.12.1. Overview
- 23.2.12.2. Products
- 23.2.12.3. SWOT Analysis
- 23.2.12.4. Recent Developments
- 23.2.12.5. Financials (Based on Availability)
- 23.2.13 WuXi AppTec Inc
- 23.2.13.1. Overview
- 23.2.13.2. Products
- 23.2.13.3. SWOT Analysis
- 23.2.13.4. Recent Developments
- 23.2.13.5. Financials (Based on Availability)
- 23.2.14 Tesa Labtec GmbH (TESA SE)
- 23.2.14.1. Overview
- 23.2.14.2. Products
- 23.2.14.3. SWOT Analysis
- 23.2.14.4. Recent Developments
- 23.2.14.5. Financials (Based on Availability)
- 23.2.15 Patheon Inc (Thermo Fisher Scientific Inc )
- 23.2.15.1. Overview
- 23.2.15.2. Products
- 23.2.15.3. SWOT Analysis
- 23.2.15.4. Recent Developments
- 23.2.15.5. Financials (Based on Availability)
- 23.2.16 Syneos Health Inc
- 23.2.16.1. Overview
- 23.2.16.2. Products
- 23.2.16.3. SWOT Analysis
- 23.2.16.4. Recent Developments
- 23.2.16.5. Financials (Based on Availability)
- 23.2.17 IQVIA Holdings Inc
- 23.2.17.1. Overview
- 23.2.17.2. Products
- 23.2.17.3. SWOT Analysis
- 23.2.17.4. Recent Developments
- 23.2.17.5. Financials (Based on Availability)
- 23.2.18 ARX LLC
- 23.2.18.1. Overview
- 23.2.18.2. Products
- 23.2.18.3. SWOT Analysis
- 23.2.18.4. Recent Developments
- 23.2.18.5. Financials (Based on Availability)
- 23.2.19 Tapemark
- 23.2.19.1. Overview
- 23.2.19.2. Products
- 23.2.19.3. SWOT Analysis
- 23.2.19.4. Recent Developments
- 23.2.19.5. Financials (Based on Availability)
- 23.2.20 Catalent Inc
- 23.2.20.1. Overview
- 23.2.20.2. Products
- 23.2.20.3. SWOT Analysis
- 23.2.20.4. Recent Developments
- 23.2.20.5. Financials (Based on Availability)
- 23.2.21 Boehringer Ingelheim Group
- 23.2.21.1. Overview
- 23.2.21.2. Products
- 23.2.21.3. SWOT Analysis
- 23.2.21.4. Recent Developments
- 23.2.21.5. Financials (Based on Availability)
- 23.2.22 Novotech Pty Ltd
- 23.2.22.1. Overview
- 23.2.22.2. Products
- 23.2.22.3. SWOT Analysis
- 23.2.22.4. Recent Developments
- 23.2.22.5. Financials (Based on Availability)
- 23.2.23 LabCorp Drug Development
- 23.2.23.1. Overview
- 23.2.23.2. Products
- 23.2.23.3. SWOT Analysis
- 23.2.23.4. Recent Developments
- 23.2.23.5. Financials (Based on Availability)
- 23.2.24 Aenova Holding GmbH
- 23.2.24.1. Overview
- 23.2.24.2. Products
- 23.2.24.3. SWOT Analysis
- 23.2.24.4. Recent Developments
- 23.2.24.5. Financials (Based on Availability)
- 23.2.25 Recipharm AB
- 23.2.25.1. Overview
- 23.2.25.2. Products
- 23.2.25.3. SWOT Analysis
- 23.2.25.4. Recent Developments
- 23.2.25.5. Financials (Based on Availability)
- 23.2.26 Sagimet Biosciences (3V Biosciences Inc )*List Not Exhaustive
- 23.2.26.1. Overview
- 23.2.26.2. Products
- 23.2.26.3. SWOT Analysis
- 23.2.26.4. Recent Developments
- 23.2.26.5. Financials (Based on Availability)
- 23.2.27 Baxter Biopharma Solutions (Baxter International Inc )
- 23.2.27.1. Overview
- 23.2.27.2. Products
- 23.2.27.3. SWOT Analysis
- 23.2.27.4. Recent Developments
- 23.2.27.5. Financials (Based on Availability)
- 23.2.28 Quanticate Ltd
- 23.2.28.1. Overview
- 23.2.28.2. Products
- 23.2.28.3. SWOT Analysis
- 23.2.28.4. Recent Developments
- 23.2.28.5. Financials (Based on Availability)
- 23.2.1 LSK Global Pharma Service Co Ltd
List of Figures
- Figure 1: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Breakdown (Million, %) by Region 2024 & 2032
- Figure 2: North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Country 2024 & 2032
- Figure 3: North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Country 2024 & 2032
- Figure 4: Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Country 2024 & 2032
- Figure 5: Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Country 2024 & 2032
- Figure 6: Asia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Country 2024 & 2032
- Figure 7: Asia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Country 2024 & 2032
- Figure 8: Australia and New Zealand Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Country 2024 & 2032
- Figure 9: Australia and New Zealand Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Country 2024 & 2032
- Figure 10: Latin America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Country 2024 & 2032
- Figure 11: Latin America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Country 2024 & 2032
- Figure 12: Middle East and Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Country 2024 & 2032
- Figure 13: Middle East and Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Country 2024 & 2032
- Figure 14: North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Service Type CMO Segment 2024 & 2032
- Figure 15: North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Service Type CMO Segment 2024 & 2032
- Figure 16: North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Research Phase CRO Segment 2024 & 2032
- Figure 17: North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Research Phase CRO Segment 2024 & 2032
- Figure 18: North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Country 2024 & 2032
- Figure 19: North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Country 2024 & 2032
- Figure 20: Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Service Type CMO Segment 2024 & 2032
- Figure 21: Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Service Type CMO Segment 2024 & 2032
- Figure 22: Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Research Phase CRO Segment 2024 & 2032
- Figure 23: Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Research Phase CRO Segment 2024 & 2032
- Figure 24: Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Country 2024 & 2032
- Figure 25: Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Country 2024 & 2032
- Figure 26: Asia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Service Type CMO Segment 2024 & 2032
- Figure 27: Asia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Service Type CMO Segment 2024 & 2032
- Figure 28: Asia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Research Phase CRO Segment 2024 & 2032
- Figure 29: Asia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Research Phase CRO Segment 2024 & 2032
- Figure 30: Asia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Country 2024 & 2032
- Figure 31: Asia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Country 2024 & 2032
- Figure 32: Latin America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Service Type CMO Segment 2024 & 2032
- Figure 33: Latin America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Service Type CMO Segment 2024 & 2032
- Figure 34: Latin America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Research Phase CRO Segment 2024 & 2032
- Figure 35: Latin America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Research Phase CRO Segment 2024 & 2032
- Figure 36: Latin America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Country 2024 & 2032
- Figure 37: Latin America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Country 2024 & 2032
- Figure 38: Middle East and Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Service Type CMO Segment 2024 & 2032
- Figure 39: Middle East and Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Service Type CMO Segment 2024 & 2032
- Figure 40: Middle East and Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Research Phase CRO Segment 2024 & 2032
- Figure 41: Middle East and Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Research Phase CRO Segment 2024 & 2032
- Figure 42: Middle East and Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Country 2024 & 2032
- Figure 43: Middle East and Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Country 2024 & 2032
- Figure 44: North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Service Type CMO Segment 2024 & 2032
- Figure 45: North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Service Type CMO Segment 2024 & 2032
- Figure 46: North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Research Phase CRO Segment 2024 & 2032
- Figure 47: North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Research Phase CRO Segment 2024 & 2032
- Figure 48: North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Country 2024 & 2032
- Figure 49: North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Country 2024 & 2032
- Figure 50: Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Service Type CMO Segment 2024 & 2032
- Figure 51: Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Service Type CMO Segment 2024 & 2032
- Figure 52: Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Research Phase CRO Segment 2024 & 2032
- Figure 53: Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Research Phase CRO Segment 2024 & 2032
- Figure 54: Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Country 2024 & 2032
- Figure 55: Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Country 2024 & 2032
- Figure 56: Asia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Service Type CMO Segment 2024 & 2032
- Figure 57: Asia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Service Type CMO Segment 2024 & 2032
- Figure 58: Asia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Research Phase CRO Segment 2024 & 2032
- Figure 59: Asia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Research Phase CRO Segment 2024 & 2032
- Figure 60: Asia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Country 2024 & 2032
- Figure 61: Asia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Country 2024 & 2032
- Figure 62: Australia and New Zealand Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Service Type CMO Segment 2024 & 2032
- Figure 63: Australia and New Zealand Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Service Type CMO Segment 2024 & 2032
- Figure 64: Australia and New Zealand Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Research Phase CRO Segment 2024 & 2032
- Figure 65: Australia and New Zealand Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Research Phase CRO Segment 2024 & 2032
- Figure 66: Australia and New Zealand Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Country 2024 & 2032
- Figure 67: Australia and New Zealand Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Country 2024 & 2032
- Figure 68: Latin America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Service Type CMO Segment 2024 & 2032
- Figure 69: Latin America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Service Type CMO Segment 2024 & 2032
- Figure 70: Latin America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Research Phase CRO Segment 2024 & 2032
- Figure 71: Latin America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Research Phase CRO Segment 2024 & 2032
- Figure 72: Latin America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Country 2024 & 2032
- Figure 73: Latin America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Country 2024 & 2032
- Figure 74: Middle East and Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Service Type CMO Segment 2024 & 2032
- Figure 75: Middle East and Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Service Type CMO Segment 2024 & 2032
- Figure 76: Middle East and Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Research Phase CRO Segment 2024 & 2032
- Figure 77: Middle East and Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Research Phase CRO Segment 2024 & 2032
- Figure 78: Middle East and Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Country 2024 & 2032
- Figure 79: Middle East and Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Country 2024 & 2032
List of Tables
- Table 1: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Region 2019 & 2032
- Table 2: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Service Type CMO Segment 2019 & 2032
- Table 3: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Research Phase CRO Segment 2019 & 2032
- Table 4: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Region 2019 & 2032
- Table 5: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Country 2019 & 2032
- Table 6: Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 7: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Country 2019 & 2032
- Table 8: Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 9: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Country 2019 & 2032
- Table 10: Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 11: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Country 2019 & 2032
- Table 12: Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 13: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Country 2019 & 2032
- Table 14: Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 15: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Country 2019 & 2032
- Table 16: Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 17: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Service Type CMO Segment 2019 & 2032
- Table 18: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Research Phase CRO Segment 2019 & 2032
- Table 19: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Country 2019 & 2032
- Table 20: United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 21: Canada Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 22: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Service Type CMO Segment 2019 & 2032
- Table 23: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Research Phase CRO Segment 2019 & 2032
- Table 24: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Country 2019 & 2032
- Table 25: United Kingdom Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 26: Germany Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 27: France Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 28: Italy Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 29: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Service Type CMO Segment 2019 & 2032
- Table 30: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Research Phase CRO Segment 2019 & 2032
- Table 31: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Country 2019 & 2032
- Table 32: China Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 33: India Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 34: Japan Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 35: Australia and New Zealand Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 36: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Service Type CMO Segment 2019 & 2032
- Table 37: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Research Phase CRO Segment 2019 & 2032
- Table 38: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Country 2019 & 2032
- Table 39: Brazil Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 40: Mexico Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 41: Argentina Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 42: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Service Type CMO Segment 2019 & 2032
- Table 43: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Research Phase CRO Segment 2019 & 2032
- Table 44: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Country 2019 & 2032
- Table 45: United Arab Emirates Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 46: Saudi Arabia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 47: South Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 48: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Service Type CMO Segment 2019 & 2032
- Table 49: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Research Phase CRO Segment 2019 & 2032
- Table 50: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Country 2019 & 2032
- Table 51: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Service Type CMO Segment 2019 & 2032
- Table 52: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Research Phase CRO Segment 2019 & 2032
- Table 53: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Country 2019 & 2032
- Table 54: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Service Type CMO Segment 2019 & 2032
- Table 55: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Research Phase CRO Segment 2019 & 2032
- Table 56: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Country 2019 & 2032
- Table 57: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Service Type CMO Segment 2019 & 2032
- Table 58: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Research Phase CRO Segment 2019 & 2032
- Table 59: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Country 2019 & 2032
- Table 60: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Service Type CMO Segment 2019 & 2032
- Table 61: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Research Phase CRO Segment 2019 & 2032
- Table 62: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Country 2019 & 2032
- Table 63: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Service Type CMO Segment 2019 & 2032
- Table 64: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Research Phase CRO Segment 2019 & 2032
- Table 65: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Country 2019 & 2032
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market?
The projected CAGR is approximately 6.41%.
2. Which companies are prominent players in the Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market?
Key companies in the market include LSK Global Pharma Service Co Ltd, Pharmaceutical Product Development LLC (Thermo Fisher Scientific Inc ), Hangzhou Tigermed Consulting Co Ltd, Famar SA, PAREXEL International Corporation, CMIC Holdings Co Ltd, PRA Health Sciences Inc (Icon PLC), Lonza Group, Pfizer CentreSource, SGS Life Science Services SA, Samsung Bioepis Co Ltd, Jubilant Pharmova Ltd, WuXi AppTec Inc, Tesa Labtec GmbH (TESA SE), Patheon Inc (Thermo Fisher Scientific Inc ), Syneos Health Inc, IQVIA Holdings Inc, ARX LLC, Tapemark, Catalent Inc, Boehringer Ingelheim Group, Novotech Pty Ltd, LabCorp Drug Development, Aenova Holding GmbH, Recipharm AB, Sagimet Biosciences (3V Biosciences Inc )*List Not Exhaustive, Baxter Biopharma Solutions (Baxter International Inc ), Quanticate Ltd.
3. What are the main segments of the Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market?
The market segments include Service Type CMO Segment, Research Phase CRO Segment.
4. Can you provide details about the market size?
The market size is estimated to be USD 243.29 Million as of 2022.
5. What are some drivers contributing to market growth?
Increasing Outsourcing Volume by Big Pharmaceutical Companies; Advent of CDMO Model into the Market; Increasing Investment in R&D.
6. What are the notable trends driving market growth?
Increasing Investment in R&D Drives the Market.
7. Are there any restraints impacting market growth?
Increasing Lead Time and Logistics Costs; Stringent Regulatory Requirements; Capacity Utilization Issues Affecting the Profitability of CMOs.
8. Can you provide examples of recent developments in the market?
January 2024 - A new collaboration was announced jointly by FAMAR and Lavipharm, two leading pharmaceutical companies. FAMAR is a leading provider of development and manufacturing services for pharmaceutical and cosmetic products (CDMO) and one of the major CDMO players in Europe. Lavipharm is a research and development (R&D) company that manufactures, imports, sells, and distributes pharmaceuticals and healthcare products in Greece.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in Million.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market?
To stay informed about further developments, trends, and reports in the Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
